人乳頭狀瘤病毒感染和復(fù)發(fā)性尖銳濕疣與細(xì)胞免疫水平的關(guān)系研究
本文選題:人乳頭狀瘤病毒 + 復(fù)發(fā) ; 參考:《中華醫(yī)院感染學(xué)雜志》2017年11期
【摘要】:目的探討人乳頭狀瘤病毒(HPV)感染和復(fù)發(fā)性尖銳濕疣細(xì)胞皮膚免疫水平的關(guān)系,為臨床預(yù)防尖銳濕疣復(fù)發(fā)提供理論依據(jù)。方法選取2015年1月-2016年6月在醫(yī)院性病科門診治療的尖銳濕疣患者136例,分為復(fù)發(fā)組85例和未復(fù)發(fā)組51例,比較兩組患者不同HPV感染亞型分布以及HPV基因型,比較兩組患者外周T淋巴細(xì)胞亞群分布的差異。結(jié)果復(fù)發(fā)組患者高危型HPV分布率為69.4%顯著高于未復(fù)發(fā)組31.4%,未復(fù)發(fā)組患者低危型HPV分布率為68.6%顯著高于復(fù)發(fā)組30.6%,差異有統(tǒng)計(jì)學(xué)意義(P0.05);復(fù)發(fā)組與未復(fù)發(fā)組患者HPV感染均以低危型HPV6,HPV11以及HPV43為主,未復(fù)發(fā)組檢測到高危型基因較少,復(fù)發(fā)組患者檢測到高危型基因較多;復(fù)發(fā)組患者CD3+含量(66.8±7.5%),CD_4~+含量(32.8±5.3%),CD_4~+/CD_8~+比值(0.8±0.1)均顯著低于未復(fù)發(fā)組CD3+含量(75.4±8.3%),CD_4~+含量(39.2±4.8%),CD_4~+/CD_8~+比值(1.2±0.2),復(fù)發(fā)組患者CD_8~+含量(40.3±4.8%)顯著高于未復(fù)發(fā)組(32.5±5.2%),差異有統(tǒng)計(jì)學(xué)意義(P0.05);治療3個月后,復(fù)發(fā)組患者CD3+(64.8±6.1%),CD_4~+含量(31.5±5.4%),CD_4~+/CD_8~+比值(0.8±0.1)均顯著低于未復(fù)發(fā)組患者CD3+(75.7±8.5%),CD_4~+含量(38.1±4.6%),CD_4~+/CD_8~+比值(1.1±0.2),復(fù)發(fā)組患者CD_8~+含量(41.6±4.5%)顯著高于未復(fù)發(fā)組(33.7±5.5%),差異有統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論尖銳濕疣患者HPV感染的亞基因型和患者治療后復(fù)發(fā)存在密切的聯(lián)系,尖銳濕疣患者在接受治療前的細(xì)胞免疫水平與疾病復(fù)發(fā)之間存在密切聯(lián)系,為臨床預(yù)防尖銳濕疣的復(fù)發(fā)以及有效治療尖銳濕疣的復(fù)發(fā)提供科學(xué)依據(jù)。
[Abstract]:Objective to investigate the relationship between human papillomavirus (HPV) infection and skin immune level of recurrent condyloma acuminatum cells, and to provide theoretical basis for clinical prevention of recurrence of condyloma acuminatum. Methods from January 2015 to June 2016, 136 patients with condyloma acuminatum were divided into recurrent group (n = 85) and non-recurrent group (n = 51). The distribution of different HPV infection subtypes and HPV genotype were compared between the two groups. To compare the distribution of peripheral T lymphocyte subsets between the two groups. Results the distribution rate of high risk HPV in recurrent group was 69.4% higher than that in non-recurrence group 31.44.The distribution rate of low-risk HPV in non-recurrence group was 68.6%, which was significantly higher than that in recurrent group (30.6%), the difference was significant (P 0.05), and the HPV infection in recurrent group and non-recurrence group was significantly higher than that in non-recurrence group (P < 0.05). Low risk type HPV6, HPV11 and HPV43 were the main types. High risk genes were detected less in non-recurrence group and more in relapse group. The CD3 content in patients with recurrence was significantly lower than that in patients without recurrence (66.8 鹵7.5and 32.8 鹵5.3) and the ratio of CD4- / -CD8- (0.8 鹵0.1) was significantly lower than that in patients without recurrence (75.4 鹵8.3C), and the ratio of CD4-% CD8- (8-) was 1.2 鹵0.2in patients with recurrence, and 40.3 鹵4.8in patients with recurrence, which was significantly higher than that in patients without recurrence (32.5 鹵5.2cm), and the difference was significant after 3 months of treatment, the difference was significant (P 0.05). The CD4 ~ content of CD3 in the patients with recurrence (64.8 鹵6.1) was significantly lower than that in the patients without recurrence (31.5 鹵5.4) and the ratio of CD4- / CD8- (0.8 鹵0.1) was significantly lower than that in the patients without recurrence (75.7 鹵8.5). The ratio of CD4- / -CD8 ~ + in patients with recurrence was significantly higher than that in the patients without recurrence (P 0.05). There was a significant difference between the patients with recurrence and those without recurrence (P 0.05). Conclusion the subgenotype of HPV infection in condyloma acuminatum patients is closely related to the recurrence after treatment, and the cellular immunity level of condyloma acuminatum patients before treatment is closely related to the recurrence of the disease. To prevent the recurrence of condyloma acuminatum and to effectively treat the recurrence of condyloma acuminatum.
【作者單位】: 廣東省人民醫(yī)院廣東省醫(yī)學(xué)科學(xué)院皮膚科;
【基金】:廣東省醫(yī)學(xué)科學(xué)技術(shù)研究基金資助項(xiàng)目(A2015148)
【分類號】:R752.53
【相似文獻(xiàn)】
相關(guān)期刊論文 前10條
1 張昕;中西醫(yī)結(jié)合治療復(fù)發(fā)性尖銳濕疣58例[J];實(shí)用中醫(yī)藥雜志;2000年01期
2 梁伶;復(fù)發(fā)性尖銳濕疣誘發(fā)因素的探討[J];廣西醫(yī)科大學(xué)學(xué)報(bào);2001年03期
3 聶磊;大范圍激光聯(lián)合更昔洛韋治療復(fù)發(fā)性尖銳濕疣的療效觀察[J];河南大學(xué)學(xué)報(bào)(醫(yī)學(xué)科學(xué)版);2001年03期
4 梁鳳英;36例復(fù)發(fā)性尖銳濕疣治療與分析[J];中原醫(yī)刊;2001年04期
5 劉玉翠,趙廣瓊,袁偉;復(fù)發(fā)性尖銳濕疣282例臨床分析[J];遵義醫(yī)學(xué)院學(xué)報(bào);2001年06期
6 史永儉,張春敏,王頻,魏國;復(fù)發(fā)性尖銳濕疣患者治療前后外周血T細(xì)胞亞群的檢測[J];中華皮膚科雜志;2002年03期
7 鄭萬方,張定子,張怡明;復(fù)發(fā)性尖銳濕疣32例分析[J];河北醫(yī)學(xué);2002年08期
8 唐俊明,賴勁東;中西醫(yī)結(jié)合治療復(fù)發(fā)性尖銳濕疣療效觀察[J];川北醫(yī)學(xué)院學(xué)報(bào);2002年04期
9 吳洲;疣體種植結(jié)合中藥治療復(fù)發(fā)性尖銳濕疣16例[J];皮膚病與性病;2002年03期
10 黃大珍;中西醫(yī)結(jié)合治療反復(fù)復(fù)發(fā)性尖銳濕疣20例[J];現(xiàn)代中西醫(yī)結(jié)合雜志;2002年09期
相關(guān)會議論文 前10條
1 江光明;yす,
本文編號:1932071
本文鏈接:http://sikaile.net/yixuelunwen/pifb/1932071.html